CG Oncology Q1 FY26 net loss widens to $60.2 million; revenue rises to $1.08 million

CG Oncology, Inc.

CG Oncology, Inc.

CGON

0.00
  • CG Oncology posted a net loss of $60.2 million, or $(0.71) per share, for first-quarter 2026, widening from a $34.5 million loss a year earlier.
  • Revenue rose to $1.08 million from $52,000, while operating costs and expenses climbed to $67.47 million from $42.26 million.
  • R&D expenses increased to $43.7 million from $27.5 million, while G&A expenses rose to $20.8 million from $14.8 million.
  • Cash, cash equivalents, and marketable securities totaled $1.1 billion as of March 31, up from $742.2 million at year-end, following $391.4 million in net ATM proceeds; cash runway projected through 2029.
  • BLA completion for cretostimogene in HR BCG-unresponsive NMIBC expected in 4Q 2026, with Phase 3 PIVOT-006 topline data due in 1H 2026 and CORE-008 Cohort CX combination results slated for presentation at AUA 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080830PRIMZONEFULLFEED9716188) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.